IL-22/IL-22R1 pathway enhances cholangiocarcinoma progression via ERK1/2 activation

Figure 9 Protein expression levels and in vivo tumor growth of cholangiocarcinoma cells following ERK inhibitor treatment. A: Western blot expression levels of related oncogenic proteins in HuCCT1 and RBE cells from different treatment groups, along with the results of quantitative analysis of Western blot among the groups; B: Representative images of subcutaneous xenograft tumor tissue samples from nude mice in different treatment groups, along with quantitative analysis results of tumor weight and volume. ^aP < 0.05, ^bP < 0.01, ^cP < 0.001. NC: Negative control.